Quellen:
- 1
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ.
Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease.
N Engl J Med.
2003;
348
1333-1341
- 2
Winblad B, Poritis N.
Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in
severely demented patients during treatment with memantine).
J Geriatr Psychiatry.
1999;
14
135-146
- 3
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I.
Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer
disease already receiving donepezil: a randomized controlled trial.
JAMA.
2004;
291
317-324
- 4
Gauthier S, Wirth Y, Möbius HJ.
Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis
of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
Int J Geriatr Psychiatry.
2005;
20
459-464
- 5
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ.
A 24-week open-label extension study of memantine in moderate to severe Alzheimer
disease.
Arch Neurol.
2006;
63
49-54
- 6
Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S.
Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled
trial.
Am J Geriatr Psychiatry.
2006;
14
704-715
1 zugelassen ist Memantine zur Behandlung der moderaten bis schweren Alzheimer-Demenz
